INTRODUCTION
============

Autism spectrum disorder (ASD) is a neurodevelopmental disorder. There is no known efficacious pharmacotherapy for the core symptoms of ASD. Risperidone and aripiprazole are the only two medications approved by US Food and Drug Administration for irritability (aggression, self-injury, and severe tantrums) in children with ASD \[[@b1-cpn-17-556]\].

With this case report, we have aimed to present an 8-year old case with autism, which had developed hypertension due to aripiprazole use. Scarce reports exist in relevant literature, with our case being the sole patient with pre-pubertal onset.

CASE
====

A girl aged 7 years and 6 months following with the diagnosis of autism and mild mental retardation for 4 year. She applied with behavioral problems such as irritability (aggression, self-injury, and severe tantrums), inability to follow instructions and rules, repetitive and stereotypical movements, physically hurting her friends. First, psycho-education was given to the family and behavioral suggestions were made. At the end of the 3rd month, due to the continuing problems a pharmacological treatment was started with 1 mg/day aripiprazole that was used orally. Physical examination and laboratory tests, prior to treatment initiation revealed no problems in our case that had no comorbid physical illness. Body mass index (BMI) was 14.3 kg/m^2^ (15--25th percentiles), blood pressure (BP) was 110/70 mmHg (\< 90 percentile), results of the markers that determine lipid profile, liver function tests, kidney function tests, cell blood count (CBC) values were within normal ranges. The case had no previous history of any medication use for behavior problems. Since the case has partial clinical symptomatic improvement with aripiprazole, medication dose was increased to 2 mg/day after a month. With increased medication dosages, problematic behavioral and psychiatric symptoms of the case were completely eliminated and no side effect was described by the family. Symptoms or signs were not detected at monthly controls during the first 3 months. At the 6th month examination of her follow up (when 8 years old), her BMI was found as 18.1 kg/m^2^ (75--85 percentiles), and BP was 130/90 mmHg (\> 99 percentile). Her lipid profile, liver function tests, kidney function tests, CBC was found within normal limits. The case was consulted to a pediatrician and it was recommended that the family should monitor the case's BP values once a day, throughout one week. It was observed that her BP levels alternated during monitorization. On 4 days of the week, her BP values were measured as 130/90 to 140/90 mmHg; while on 3 days, the values were around 100/60 to 110/70 mmHg. No endocrinological or renovascular etiology that would provide an explanation for this condition was determined. Elevated BP values were attributed to her medication use and it was recommended to cease her medication for some time, to observe her BP values. Following the cessation of her medication regimen, her BP measures were collected once a day, for one week, once again. It was seen that her

BP values were regulated and around 100/60 to 100/70 mmHg (\< 90th percentile). BP values were assessed with 'BP Levels for Girls by Age and Height Percentile'\[[@b2-cpn-17-556]\].

DISCUSSION
==========

With this case report, we have aimed to present the clinical course of a case that had developed asymptomatic hypertension at the 6th month of her low-dose aripiprazole use 2 mg/day, and to discuss possible underlying mechanisms of this phenomenon.

Through a review of relevant literature, we came across 7 case reports that suggested aripiprazole use led to hypertension, in their clinical course and management of their cases \[[@b3-cpn-17-556]--[@b8-cpn-17-556]\]. Most of these cases, however, had some risk factors that might be attributed to the observed increase in their BP, such as old age \[[@b3-cpn-17-556],[@b5-cpn-17-556]--[@b8-cpn-17-556]\] history of a metabolic disorder (diabetes mellitus, hypertension, coronary heart disease) and multiple drug use \[[@b5-cpn-17-556]--[@b7-cpn-17-556]\]. Among these reported cases, symptoms related to hypertension had developed upon either long-term medication use, or increasing the medication doses, which had led to the recognition of the condition \[[@b3-cpn-17-556]--[@b8-cpn-17-556]\]. Rather different than these cases, hypertension had emerged at 6th month of treatment in our case and was recognized during her routine hospital visits. Her elevated BP values were back in normal ranges, within 10 days after aripiprazole treatment had been ceased.

When data regarding effects of atypical antipsychotics in children, rates of weight gain as the side effect seem to be similar to those observed in adults, though the quantity of weight gain seem to be much more than what is seen in adults \[[@b9-cpn-17-556]\]. In one cross-sectional study, it was found that subjects that had used antipsychotics longer than 12 months had significantly higher BMI, compared to those that had used antipsychotics less than one month \[[@b10-cpn-17-556]\]. It has also been reported that among children where increase in the prevalence of essential hypertension correlated well with the increase in BMI, following add- on of the increase in the prevalence of obesity, pediatric hypertension turned into an epidemiological problem \[[@b11-cpn-17-556]\]. Even though BMI value of our case was not regarded as indicating obesity, there was a significant difference between BMI values that had been measured prior to the initiation of treatment and after, which was conceptualized as a risk factor for hypertension. However, BP values measured in normal ranges within 10 days upon medication cessation and no observed alteration in weight, shifted the attention to aripiprazole use as the main factor for developing hypertension.

Commonly reported action mechanism of aripiprazole involves a partial agonistic effect on D3 and 5HT~1A~ receptors and an antagonistic effect on 5-HT~2A~ receptor \[[@b12-cpn-17-556]\]. Differently some authors such as Davies *et al*. \[[@b13-cpn-17-556]\] and Shapiro *et al*. \[[@b14-cpn-17-556]\] have suggested that aripiprazole might actually act as a partial agonist on 5-HT~2A~ receptor. 5-HT~2A~ receptor is known to have a role in the contraction functions of vascular smooth muscles. Therefore, it might be hypothesized that through aripiprazole acting as a partial agonist of 5-HT~2A~ receptors for some individuals, in turn, via causing vasoconstriction of vascular smooth muscles, caused elevated BP. One other reason for elevated BP measures might be related to the inhibition of nitric oxide (NO) release. In a study, it was shown that aripiprazole inhibited NO production in microglial cells \[[@b15-cpn-17-556]\]. NO is known to act as an agent that decreased BP. The hypertension could be occurred due to aripiprazole, because of inhibited NO production in the vessels. Along with these phenomena, it has also been suggested that through causing a structural alteration due to its effects on the endothelium; obesity might also decrease the bioavailability of nitric oxide and in turn, leading to emergence of hypertension \[[@b11-cpn-17-556]\]. Efficacy and side-effect profiles of these drugs are heterogeneous, with large inter-individual variability. Much of the interindividual variability in response and side effects is due to genetic factors.

Main difference in the course of our case was the fact that hypertension presented upon 6 months treatment, contrary to those reported to have developed upon acute use of the medication, and its asymptomatic nature and course in our patient. Moreover, to best of our knowledge, this has been the only case that reported such symptoms manifesting in a pre-pubertal case, so far. Clinicians need to be attentive and vigilant for this side-effect and it might be a good idea to monitor BP levels closely, if aripiprazole is to be chosen as the treatment agent. Further studies are warranted to explore and clearly identify through which mechanisms this side-effect occurs.

This case was presented as a poster in Turkish language in the 4. Prof. Dr. Selahattin enol Bahar Okulu between March 29, 2018 and April 1, 2018.
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